GLP-1 receptor agonists have transformed the management of type 2 diabetes and obesity, but their mechanism of delaying gastric emptying presents important clinical considerations
Improvement in fibrosis 1 stage without worsening of NASH was achieved in 26% with 30 mg and in 27% with 44 mg, versus 7% with placebo (p = 0.009 and p = 0.008), and resolution of NASH without worsening of fibrosis in 23% with 30 mg, 26% with 44 mg, and 37% with 15 mg, versus 2% with placebo
Myofibrillar protein synthesis (MyoPS) rose ~90% at 5 h in both groups, remaining elevated at 24 h only in the high-leucine group
David: Plus, Im sure there are some people out there who dont love the idea of self-injections
As an incretin hormone, GLP-1 increases insulin release when blood sugar rises after meals and reduces glucagon levels, helping maintain stable glucose levels
Telling Your Healthcare Provider About Semaglutide Treatment Transparency with your doctor strengthens your treatment outcomes and safety monitoring
